{"nctId":"NCT01958671","briefTitle":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","startDateStruct":{"date":"2013-10-09","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":461,"armGroups":[{"label":"Ertugliflozin 5 mg/Ertugliflozin 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ertugliflozin 5 mg","Drug: Placebo to Ertugliflozin","Drug: Metformin","Drug: Placebo to Metformin","Drug: Glimepiride"]},{"label":"Ertugliflozin 15 mg/Ertugliflozin 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ertugliflozin 5 mg","Drug: Ertugliflozin 10 mg","Drug: Metformin","Drug: Placebo to Metformin","Drug: Glimepiride"]},{"label":"Placebo/Metformin","type":"OTHER","interventionNames":["Drug: Placebo to Ertugliflozin","Drug: Metformin","Drug: Glimepiride"]}],"interventions":[{"name":"Ertugliflozin 5 mg","otherNames":["MK-8835","PF-04971729"]},{"name":"Ertugliflozin 10 mg","otherNames":["MK-8835","PF-04971729"]},{"name":"Placebo to Ertugliflozin","otherNames":[]},{"name":"Metformin","otherNames":["Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor and Metfogamma."]},{"name":"Placebo to Metformin","otherNames":[]},{"name":"Glimepiride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of T2DM in accordance to American Diabetes Association guidelines\n* Participants with no prior allowable oral anti-hyperglycemic agents (AHA) for at least 8 weeks prior to study participation or participants on a single allowable oral AHA at the start of study participation\n* Participants on a single allowable AHA must be willing to discontinue this medication at the Screening Visit (S2) and remain off this medication for the duration of the trial. Allowable oral AHAs for discontinuation are metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides or alpha-glucosidase inhibitors.\n\nExclusion Criteria:\n\n* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation\n* A clinically significant electrocardiogram abnormality\n* A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer\n* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor or metformin\n* On a blood pressure or lipid altering medication that have not been on a stable dose for at least 4 weeks prior to study participation\n* A surgical procedure within 4 weeks prior to study participation or planned major surgery during the trial\n* Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial\n* Pregnant or breast-feeding, or is expecting to conceive during the trial, including 14 days following the last dose of study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline In A1C at Week 26","description":"A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":null},{"groupId":"OG001","value":"-0.96","spread":null},{"groupId":"OG002","value":"0.20","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing An Adverse Event (AE)","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Discontinuing Study Treatment Due to an AE","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 26","description":"The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.96","spread":null},{"groupId":"OG001","value":"-43.44","spread":null},{"groupId":"OG002","value":"0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 26","description":"The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.18","spread":null},{"groupId":"OG001","value":"-3.58","spread":null},{"groupId":"OG002","value":"-1.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26","description":"A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level","description":"Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"260.32","spread":"76.110"},{"groupId":"OG001","value":"262.91","spread":"78.189"},{"groupId":"OG002","value":"256.21","spread":"76.917"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hr PPG at Week 26","description":"The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.15","spread":null},{"groupId":"OG001","value":"-62.45","spread":null},{"groupId":"OG002","value":"4.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Sitting Systolic Blood Pressure (SBP)","description":"Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130.49","spread":"13.511"},{"groupId":"OG001","value":"129.67","spread":"14.208"},{"groupId":"OG002","value":"129.80","spread":"14.464"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SBP at Week 26","description":"The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.54","spread":null},{"groupId":"OG001","value":"-3.93","spread":null},{"groupId":"OG002","value":"-2.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Sitting Diastolic Blood Pressure (DBP)","description":"Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.46","spread":"8.117"},{"groupId":"OG001","value":"78.53","spread":"7.714"},{"groupId":"OG002","value":"78.13","spread":"7.458"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DBP at Week 26","description":"The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":null},{"groupId":"OG001","value":"-1.10","spread":null},{"groupId":"OG002","value":"-0.72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":156},"commonTop":["Urinary tract infection","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis","Vulvovaginal mycotic infection"]}}}